LipoScience prices IPO at $9, 36% below original midpoint

By
A A A

LipoScience, which provides a diagnostic test to assess cardiovascular disease risk, raised $45 million on Thursday by offering 5 million shares at $9, 36% below the midpoint of the original $13-$15 range. The company cut its estimated price range to $9-$10 earlier on Thursday. LipoScience plans to list on the NASDAQ under the symbol LPDX. Barclays, UBS Investment Bank and Piper Jaffray acted as underwriters on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: LPDX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Don't Pay Up to Play REITs
Don't Pay Up to Play REITs          

Stocks

Referenced

Most Active by Volume

100,376,898
  • $17.62 ▲ 0.51%
83,231,837
  • $25.62 ▲ 1.91%
75,739,329
  • $111.78 ▼ 0.77%
65,297,937
  • $36.37 ▼ 1.76%
59,053,093
  • $47.66 ▲ 0.29%
53,482,350
  • $2.59 ▼ 0.38%
51,504,284
  • $7.34 ▲ 2.37%
51,434,656
  • $8.14 ▲ 6.96%
As of 12/19/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com